Decoding Major Depressive Disorder: A Comprehensive Review of Neurobiological Pathways, Biomarker Signatures, and Therapeutic Advances

Major depressive disorder (MDD) is a common and serious mental health disorder that arises from a complex combination of biological factors. Despite extensive scientific progress, the exact mechanisms responsible for its development are not entirely understood. Several interrelated processes—including imbalances in monoamine neurotransmitters, dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis, impaired neurogenesis and neuroplasticity, mitochondrial abnormalities, chronic neuroinflammation, and genetic as well as epigenetic influences—play important roles in the onset and continuation of depressive symptoms. Additionally, disturbances in glutamate and GABA signalling, alterations within the gut-brain axis, disruption of circadian rhythms, and defects in synaptic communication further contribute to the disorder’s complexity. Recognition of these mechanisms has guided the advancement of treatment strategies. While conventional therapies such as pharmacological antidepressants and psychotherapy continue to be widely used, innovative options—including ketamine-based treatments, neuromodulation techniques, anti-inflammatory agents, and therapies targeting the microbiome—are emerging as promising alternatives. This review summarizes the key biological pathways implicated in depression and examines both established and evolving therapeutic approaches designed to improve outcomes and support long-term patient recovery.

Major depressive disorder, Types of Depression Etiologies, Pathophysiology, Biomarkers, Neuroinflammation

1. World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: World Health Organization; 2017. [Google Scholar] [Crossref]

2. Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–2312. doi:10.1016/S0140-6736(18)31948-2. [Google Scholar] [Crossref]

3. Santomauro DF, Mantilla Herrera AM, Shadid J, Zheng P, Ashbaugh C, Pigott DM, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398:1700–1712. [Google Scholar] [Crossref]

4. Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus: a meta-analysis. Diabetologia. 2006;49:837–845. [Google Scholar] [Crossref]

5. World Health Organization. Depressive disorder (depression) [Internet]. 2023 [cited 2024 Dec 4]. Available from: https://www.who.int/news-room/fact-sheets/detail/depression [Google Scholar] [Crossref]

6. Siu AL, Bibbins-Domingo K, Grossman DC, Baumann LC, Davidson KW, US Preventive Services Task Force, et al. Screening for depression in adults: recommendation statement. JAMA. 2016;315:380. doi:10.1001/jama.2015.18392. [Google Scholar] [Crossref]

7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Association; 2013. [Google Scholar] [Crossref]

8. Caldiroli A, Capuzzi E, Tagliabue I, Capellazzi M, Marcatili M, Mucci F, et al. Augmentative pharmacological strategies in treatment-resistant major depression: a comprehensive review. Int J Mol Sci. 2021;22:13070. [Google Scholar] [Crossref]

9. Zhuo C, Li G, Lin X, Jiang D, Xu Y, Tian H, et al. The rise and fall of MRI studies in major depressive disorder. Transl Psychiatry. 2019;9:335. [Google Scholar] [Crossref]

10. Nolan M, Roman E, Nasa A, Levins KJ, O’Hanlon E, O’Keane V, et al. Hippocampal and amygdalar volume changes in major depressive disorder: a targeted review. Chronic Stress. 2020;4:2470547020944553. [Google Scholar] [Crossref]

11. Hellewell SC, Welton T, Maller JJ, Lyon M, Korgaonkar MS, Koslow SH, et al. Reduced regional gray matter patterns in major depressive disorder. Transl Psychiatry. 2019;9:176. [Google Scholar] [Crossref]

12. Schmaal L, Pozzi E, Ho TC, van Velzen LS, Veer IM, Opel N, et al. ENIGMA MDD: global neuroimaging studies of major depression. Transl Psychiatry. 2020;10:172. [Google Scholar] [Crossref]

13. Stockmeier CA, Rajkowska G. Cellular abnormalities in depression: evidence from postmortem brain tissue. Dialogues Clin Neurosci. 2004;6:185–197. [Google Scholar] [Crossref]

14. Duric V, Banasr M, Stockmeier CA, Simen AA, Newton SS, Overholser JC, et al. Altered expression of synapse and glutamate-related genes in depression. Int J Neuropsychopharmacol. 2013;16:69–82. [Google Scholar] [Crossref]

15. Li J, Seidlitz J, Suckling J, Fan F, Ji GJ, Meng Y, et al. Cortical structural differences in major depressive disorder. Nat Commun. 2021;12:1647. [Google Scholar] [Crossref]

16. Moriarty AS, Meader N, Snell KIE, et al. Predicting relapse or recurrence of depression. Br J Psychiatry. 2022;221:448–458. [Google Scholar] [Crossref]

17. Kuyken W, Byford S, Taylor RS, et al. Mindfulness-based cognitive therapy to prevent relapse. J Consult Clin Psychol. 2008;76:966–978. [Google Scholar] [Crossref]

18. Gadot R, Najera R, Hirani S, et al. Deep brain stimulation meta-analysis. J Neurol Neurosurg Psychiatry. 2022;93:1166–1173. [Google Scholar] [Crossref]

19. Łojko D, Rybakowski J. Atypical depression: current perspectives. Neuropsychiatr Dis Treat. 2017;13:2447–2456. [Google Scholar] [Crossref]

20. Guideline Development Panel for the Treatment of Depressive Disorders. Clinical practice guideline summary. Am Psychol. 2022;77:770–780. [Google Scholar] [Crossref]

21. Pjrek E, Friedrich ME, Cambioli L, et al. Light therapy in seasonal affective disorder. Psychother Psychosom. 2019;89:17–24. [Google Scholar] [Crossref]

22. Riedinger MA, van der Wee NJA, Giltay EJ, de Leeuw M. Lithium in bipolar depression. Hum Psychopharmacol. 2023;38:e2881. [Google Scholar] [Crossref]

23. Straszek SP, Licht RW, Nielsen RE, Vinberg M. Bipolar depression. Ugeskr Laeger. 2022;184:V10210821. [Google Scholar] [Crossref]

24. Hazell P. Updates in treatment of depression in children and adolescents. Curr Opin Psychiatry. 2021;34:593–599. [Google Scholar] [Crossref]

25. Alexopoulos GS. Mechanisms and treatment of late-life depression. Transl Psychiatry. 2019;9:188. [Google Scholar] [Crossref]

26. Jayasekara R, Procter N, Harrison J, et al. Cognitive behavioural therapy in older adults. J Ment Health. 2014;24:168–171. [Google Scholar] [Crossref]

27. Hare DL, Toukhsati SR, Johansson P, Jaarsma T. Howland RH. General health and comorbidity in dysthymia. Int J Psychiatry Med. 2005;23:211–238. [Google Scholar] [Crossref]

28. Wells KB, Burnam MA, Rogers W, Hays R, Camp P. Course of depression in adult outpatients. Arch Gen Psychiatry. 2002;49:788–794. [Google Scholar] [Crossref]

29. Williams JW Jr, Kerber CA, Mulrow CD, Medina A, Aguilar C. Depressive disorders in primary care. J Gen Intern Med. 2008;10:7–12. [Google Scholar] [Crossref]

30. Holsboer F, Ising M. Stress hormone regulation. Annu Rev Psychol. 2010;61:81–109. [Google Scholar] [Crossref]

31. McEwen BS, Nasca C, Gray JD. Stress effects on neuronal structure. Neuropsychopharmacology. 2016;41:3–23. [Google Scholar] [Crossref]

32. Daskalakis NP, Meijer OC, de Kloet ER. Mineralocorticoid and glucocorticoid receptors. Neurobiol Stress. 2022;18:100455. [Google Scholar] [Crossref]

33. Keller J, Gomez R, Williams G, Lembke A, Lazzeroni L, Murphy GM Jr, et al. HPA axis in major depression. Mol Psychiatry. 2017;22:527–536. [Google Scholar] [Crossref]

34. Menke A. Is the HPA axis still a target for depression? Front Psychiatry. 2019;10:101. [Google Scholar] [Crossref]

35. Block TS, Kushner H, Kalin N, Nelson C, Belanoff J, Schatzberg A. Mifepristone in psychotic depression. Biol Psychiatry. 2018;84:46–54. [Google Scholar] [Crossref]

36. Depression and cardiovascular disease. Eur Heart J. 2014;35:1365–1372. [Google Scholar] [Crossref]

37. Dunbar JA, et al. Depression and metabolic syndrome. Diabetes Care. 2008;31:2368–2373. [Google Scholar] [Crossref]

38. Fries GR, Saldana VA, Finnstein J, Rein T. Molecular pathways of major depressive disorder. Mol Psychiatry. 2023;28:284–297. [Google Scholar] [Crossref]

39. Keller J, et al. HPA axis and cognition in depression. Mol Psychiatry. 2017;22:527–536. [Google Scholar] [Crossref]

40. Dong L, Li B, Verkhratsky A, Peng L. Gene expression changes in stress. Psychopharmacology. 2015;232:2827–2835. [Google Scholar] [Crossref]

41. Xia M, et al. Sleep deprivation selectively down-regulates astrocytic 5-HT2B receptors and triggers depressive-like behaviors. Neurosci Bull. 2020;36:1259–1270. [Google Scholar] [Crossref]

42. De-Miguel FF, Trueta C. Synaptic and extrasynaptic secretion of serotonin. Cell Mol Neurobiol. 2005;25:297–312. [Google Scholar] [Crossref]

43. Maes M, Yirmyia R, Noraberg J, et al. The inflammatory and neurodegenerative hypothesis of depression. Metab Brain Dis. 2009;24:27–53. [Google Scholar] [Crossref]

44. Deakin JF, Graeff FG. 5-HT and mechanisms of defence. J Psychopharmacol. 1991;5:305–315. [Google Scholar] [Crossref]

45. Xue Y, Liang H, Yang R, Deng K, Tang M, Zhang M. Role of neurotrophins in depression. Behav Brain Res. 2021;404:113162. [Google Scholar] [Crossref]

46. Babaev O, Cruces Solis H, Arban R. Dopamine modulating agents and motivation-related behavior. Neuropharmacology. 2022:109056. [Google Scholar] [Crossref]

47. Mercuri NB, Federici M, Rizzo FR, et al. Long-term depression of striatal dopamine release induced by mGluRs. Front Cell Neurosci. 2021;15:798464. [Google Scholar] [Crossref]

48. Zaghmi A, Perez-Mato M, Dopico-Lopez A, Candamo-Lourido M, Campos F, Gauthier MA. Glutamate excitotoxicity and therapeutic bioconjugates. Biomacromolecules. 2022;23:1864–1872. [Google Scholar] [Crossref]

49. Zaghmi A, Perez-Mato M, Dopico-Lopez A, Candamo-Lourido M, Campos F, Gauthier MA. New perspectives for metabolite-depleting enzymes. Biomacromolecules. 2022;23:1864–1872. [Google Scholar] [Crossref]

50. Tomasetti C, Montemitro C, Fiengo ALC, et al. Glutamatergic system in major depression. Curr Pharm Des. 2019;25:381–387. [Google Scholar] [Crossref]

51. Musazzi L, Treccani G, Mallei A, Popoli M. Antidepressants and glutamate system. Biol Psychiatry. 2013;73:1180–1188. [Google Scholar] [Crossref]

52. Kadriu B, Musazzi L, Henter ID, Graves M, Popoli M, Zarate CA Jr. Glutamatergic neurotransmission and antidepressants. Int J Neuropsychopharmacol. 2019;22:119–135. [Google Scholar] [Crossref]

53. Beurel E, Grieco SF, Amadei C, Downey K, Jope RS. Ketamine-induced GSK-3 inhibition. Bipolar Disord. 2016;18:473–480. [Google Scholar] [Crossref]

54. Gould TD, O’Donnell KC, Dow ER, Du J, Chen G, Manji HK. AMPA receptors in antidepressant effects. Neuropharmacology. 2008;54:577–587. [Google Scholar] [Crossref]

55. Schur RR, Draisma LW, Wijnen JP, et al. Brain GABA levels across psychiatric disorders. Hum Brain Mapp. 2016;37:3337–3352. [Google Scholar] [Crossref]

56. Ren Z, Pribiag H, Jefferson SJ, et al. GABAergic deficits and ketamine treatment. Biol Psychiatry. 2016;80:457–468. [Google Scholar] [Crossref]

57. Coplan JD, Andrews MW, Rosenblum LA, et al. Elevated CRF after early-life stress. Proc Natl Acad Sci USA. 1996;93:1619–1623. [Google Scholar] [Crossref]

58. de Kloet ER, Reul JMHM, Sutanto W. Corticosteroids and the brain. J Steroid Biochem Mol Biol. 1990;37:387–394. [Google Scholar] [Crossref]

59. de Kloet ER. Steroids, stability and stress. Front Neuroendocrinol. 1995;16:416–425. [Google Scholar] [Crossref]

60. Dallman MF, Yates FE. Corticosteroid feedback mechanisms. Ann N Y Acad Sci. 1969;156:696–721. [Google Scholar] [Crossref]

61. Young EA, Haskett RF, Murphy-Weinberg V, et al. Loss of glucocorticoid feedback in depression. Arch Gen Psychiatry. 1991;48:693–699. [Google Scholar] [Crossref]

62. Young EA, Haskett RF, Murphy-Weinberg V, et al. Loss of glucocorticoid fast feedback in depression. Arch Gen Psychiatry. 1991;48:693–699. [Google Scholar] [Crossref]

63. Jeon SW, Kim YK. Inflammation-induced depression. J Neuroimmunol. 2017;313:92–98. [Google Scholar] [Crossref]

64. Miller AH, Raison CL. Role of inflammation in depression. Nat Rev Immunol. 2016;16:22–34. [Google Scholar] [Crossref]

65. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Depression and inflammatory markers. Am J Cardiol. 2002;90:1279–1283. [Google Scholar] [Crossref]

66. Mao R, Zhang C, Chen J, et al. Cytokine levels in depression. J Affect Disord. 2018;237:65–72. [Google Scholar] [Crossref]

67. Li Z, Qi D, Chen J, et al. Venlafaxine and TNF-alpha levels. Psychoneuroendocrinology. 2013;38:107–114. [Google Scholar] [Crossref]

68. Kohler CA, Freitas TH, Stubbs B, et al. Cytokine changes after antidepressants. Mol Neurobiol. 2018;55:4195–4206. [Google Scholar] [Crossref]

69. Syed SA, Beurel E, Loewenstein DA, et al. Inflammatory pathways and treatment response. Neuron. 2018;99:914–924. [Google Scholar] [Crossref]

70. Bavaresco DV, Uggioni MLR, Ferraz SD, et al. Infliximab in depression. Pharmacol Biochem Behav. 2020;188:172838. [Google Scholar] [Crossref]

71. Innes S, Pariante CM, Borsini A. Microglia and synaptic plasticity. Psychoneuroendocrinology. 2019;102:236–247. [Google Scholar] [Crossref]

72. Weng L, Dong S, Wang S, Yi L, Geng D. Neuroinflammation in depression. Physiol Behav. 2019;204:33–40. [Google Scholar] [Crossref]

73. Virmani G, D'Almeida P, Nandi A, Marathe S. Chronic stress effects on astrocytes. Eur J Neurosci. 2021;54:5730–5746. [Google Scholar] [Crossref]

74. Sochocka M, Diniz BS, Leszek J. Inflammatory response in CNS. Mol Neurobiol. 2017;54:8071–8089. [Google Scholar] [Crossref]

75. Kessing LV, Hansen MG, Andersen PK. Risk of recurrence in depression. Acta Psychiatr Scand. 2004;109:339–344. [Google Scholar] [Crossref]

76. Sheline YI, Gado MH, Kraemer HC. Depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516–1518. [Google Scholar] [Crossref]

77. Hasler G, Fromm S, Alvarez RP. Cerebral blood flow in anxiety. J Neurosci. 2007;27:6313–6319. [Google Scholar] [Crossref]

78. Frodl TS, Koutsouleris N, Bottlender R. Brain morphology in depression. Arch Gen Psychiatry. 2008;65:1156–1165. [Google Scholar] [Crossref]

79. Martinowich K, Manji H, Lu B. BDNF in depression. Nat Neurosci. 2007;10:1089–1093. [Google Scholar] [Crossref]

80. Strawbridge R, Young AH, Cleare AJ. Biomarkers for depression. Neuropsychiatr Dis Treat. 2017;13:1245–1262. [Google Scholar] [Crossref]

81. Jani BD, McLean G, Nicholl BI, et al. Risk assessment and prediction using blood-based biomarkers in depression. Front Hum Neurosci. 2015;9:18. [Google Scholar] [Crossref]

82. Paganin W, Signorini S. Inflammatory biomarkers in depression: scoping review. BJPsych Open. 2024;10:e165. [Google Scholar] [Crossref]

83. Licinio J, Wong ML. Advances in depression research. Mol Psychiatry. 2020;25:1356–1360. [Google Scholar] [Crossref]

84. Coleman JRI, Peyrot WJ, Purves KL, Davis KAS, Rayner C, Choi SW, et al. Genome-wide gene–environment analyses of major depressive disorder. Mol Psychiatry. 2020;25:1430–1446. [Google Scholar] [Crossref]

85. Taub DD. Neuroendocrine interactions in the immune system. Cell Immunol. 2008;252:1–6. [Google Scholar] [Crossref]

86. Felger JC, Lotrich FE. Inflammatory cytokines in depression. Neuroscience. 2013;246:199–229. [Google Scholar] [Crossref]

87. Hiles SA, Attia J, Baker AL, et al. Changes in IL-6, CRP and IL-10 in depression. Brain Behav Immun. 2010;24(Suppl 1):S44. [Google Scholar] [Crossref]

88. Galvão ACM, Almeida RN, Júnior GMS, et al. Biomarkers of major depression diagnosis and chronicity. PLoS One. 2021;16:e0257251. [Google Scholar] [Crossref]

89. Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression. Neuropsychopharmacology. 2011;36:2375–2394. [Google Scholar] [Crossref]

90. Autry AE, Monteggia LM. Brain-derived neurotrophic factor in neuropsychiatric disorders. Pharmacol Rev. 2012;64:238–258. [Google Scholar] [Crossref]

91. Duarte NS, Corrêa LMA, Assunção LR, et al. Hormonal dysregulation in depression. Open J Depress. 2017;6:69–78. [Google Scholar] [Crossref]

92. Zajkowska Z, Gullett N, Walsh A, Zonca V, Pedersen GA, Souza L, et al. Cortisol and development of depression. Psychoneuroendocrinology. 2022;136:105625. [Google Scholar] [Crossref]

93. Fischer S, Strawbridge R, Vives AH, Cleare AJ. Cortisol as predictor of therapy response. Br J Psychiatry. 2017;210:105–109. [Google Scholar] [Crossref]

94. Chocano-Bedoya PO, Mirzaei F, O’Reilly EJ, et al. CRP, IL-6 and depression. J Affect Disord. 2014;163:25–32. [Google Scholar] [Crossref]

95. Pasquali MA, Harlow BL, Soares CN, et al. Neurotrophic and inflammatory markers in depression. Eur Arch Psychiatry Clin Neurosci. 2017;268:771–781. [Google Scholar] [Crossref]

96. Campo JV, Dahl RE, Williamson DE, et al. Serotonergic challenge and emotional disorders. J Am Acad Child Adolesc Psychiatry. 2003;42:1221–1226. [Google Scholar] [Crossref]

97. Pg F, Jd M, A P, T R, G G, D P, et al. Phosphorylated α-synuclein as biomarker. FASEB J. 2011;25:4127–4137. [Google Scholar] [Crossref]

98. Pj L, Rj A, Ke F, et al. Depression and glycemic control: meta-analysis. Diabetes Care. 2000;23:934–942. [Google Scholar] [Crossref]

99. Carvalho AF, Rocha DQC, McIntyre RS, et al. Adipokines as depression biomarkers. J Psychiatr Res. 2014;59:28–37. Pennisi E. Gut bacteria linked to mental well-being and depression. Science. 2019;363:569. [Google Scholar] [Crossref]

100. Naseribafrouei A, Hestad K, Avershina E, et al. Fecal microbiota and depression. Neurogastroenterol Motil. 2014;26:1155–1162. [Google Scholar] [Crossref]

101. Yang J, Zheng P, Li Y, et al. Bacterial and metabolic signatures in depression. Sci Adv. 2020;6:eaba8555. [Google Scholar] [Crossref]

102. Liu L, Wang H, Zhang H, et al. Gut microbiome in depression. Adv Sci. 2022;9:e2203707. [Google Scholar] [Crossref]

103. Huang TT, Lai JB, Du YL, Xu Y, Ruan LM, Hu SH. Gut microbiota in mood disorders. Front Genet. 2019;10:98. [Google Scholar] [Crossref]

104. Trzeciak P, Herbet M. Microbiome and psychobiotics in depression. Nutrients. 2021;13:927. [Google Scholar] [Crossref]

105. Johnson D, Thurairajasingam S, Letchumanan V, Chan KG, Lee LH. Probiotics in depression. Nutrients. 2021;13:1728. [Google Scholar] [Crossref]

106. Suda K, Matsuda K. Gut-brain axis mechanisms. Int J Mol Sci. 2022;23:1172. [Google Scholar] [Crossref]

107. Jiang C, Salton SR. Neurotrophins in major depressive disorder. Transl Neurosci. 2013;4:46–58. [Google Scholar] [Crossref]

108. Lu YR, Fu XY, Shi LG, et al. Amino acids and nitric oxide in depression. BMC Psychiatry. 2014;14:123. [Google Scholar] [Crossref]

109. Koochakpoor G, Salari-Moghaddam A, Keshteli AH, et al. Amino acids and depression. Nutr J. 2021;20:11. [Google Scholar] [Crossref]

110. Islam MR, Ali S, Karmoker JR, et al. Antioxidants in major depressive disorder. BMC Psychiatry. 2020;20:333. [Google Scholar] [Crossref]

111. Choi W, Kang HJ, Lim JY, et al. Serum serotonin and remission in depression. Clin Psychopharmacol Neurosci. 2022;20:248–258. [Google Scholar] [Crossref]

112. Sendi S, Fischer S, Papadopoulos A, et al. Childhood trauma and cortisol in depression. Psychol Med. 2023;53:6397–6402. [Google Scholar] [Crossref]

113. Mi Z. Thyroid hormone abnormalities in depression. J Psychiatry. 2014. [Google Scholar] [Crossref]

114. Pitsillou E, Bresnehan SM, Kagarakis EA, et al. Molecular basis of major depressive disorder. Mol Biol Rep. 2020;47:753–770. [Google Scholar] [Crossref]

115. Lee MY, Kim EY, Kim SH, et al. Serum protein biomarkers in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016;69:60–68. [Google Scholar] [Crossref]

116. Chen D, Wang X, Voon V, et al. Neurophysiological stratification of MDD. Nat Ment Health. 2023;1:863–875. [Google Scholar] [Crossref]

117. Zhao Y, Yang L, Sahakian BJ, et al. Brain, immunometabolic and genetic mechanisms in depression. Nat Ment Health. 2023;1:736–750. [Google Scholar] [Crossref]

118. Carpenter WT. The RDoC controversy. Am J Psychiatry. 2016;173:562–563. [Google Scholar] [Crossref]

119. Patrick CJ, Hajcak G. RDoC: translating promise into progress. Psychophysiology. 2016;53:415–424. [Google Scholar] [Crossref]

120. Auerbach RP. Developmental origins of psychiatric disorders. J Child Psychol Psychiatry. 2022;63:377–380. [Google Scholar] [Crossref]

• Artificial Intelligence in Pharmacology, Drug Safety and Toxicity
• Seroprevalence and Associated Risk Factors of Treponema Pallidum Infection among Pregnant Women Attending Antenatal Clinics in Lokoja, Kogi State
• In Silico Evaluation of Hyptis Verticillata-Derived Phytochemicals Targeting Estrogen Receptor Alpha (Erα) and Progesterone Receptor in Hormone-Dependent Breast Cancer
• A Review Article on AI in Personalized Medicine & Novel Pharamacology
• Leech Therapy (Hirudotherapy): A Comprehensive Systematic Review of Pharmacological Constituents, Mechanisms of Action, Therapeutic Applications, and Safety